Atherogenic antiphospholipid antibodies in antiphospholipid syndrome

Annals of the New York Academy of Sciences

Volumn 1108, Issue , 2007, Pages 489-496

  Kobayashi, Kazuko ^a   Lopez, Luis R ^b   Matsuura, Eiji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b Division of Medicine   (United States)

Author keywords

Antiphospholipid syndrome; Oxidized low density lipoprotein; 2 glycoprotein I

Indexed keywords

ANTIBODY; BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; PHOSPHOLIPID ANTIBODY; UNCLASSIFIED DRUG;

ANTIPHOSPHOLIPID SYNDROME; ATHEROSCLEROSIS; CONFERENCE PAPER; HUMAN; MACROPHAGE; NONHUMAN; PROTEIN BINDING; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 34948816613     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1422.052     Document Type: Conference Paper

References (35)

1. KODAMA, T., P. REDDY, C. KISHIMOTO, et al. 1988. Purification and characterization of a bovine acetyl low density lipoprotein receptor. Proc. Natl. Acad. Sci. USA 85: 9238-9242.
2. LOUGHEED, M., E.D. MOORE, D.R. SCRIVEN, et al. 1999. Uptake of oxidized LDL by macrophages differs from that of acetyl LDL and leads to expansion of an acidic endolysosomal compartment. Arterioscler. Thromb. Vasc. Biol. 19: 1881-1890.
3. HARRIS, E. N., J.K. CHAN, R.A. ASHERSON, et al. 1986. Thrombosis, recurrent fetal loss, and thrombocytopenia. Predictive value of the anticardiolipin antibody test. Arch. Intern. Med. 146: 2153-2156.
4. GINSBURG, K.S., M.H. LIANG, L. NEWCOMER, et al. 1992. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann. Intern. Med. 117: 997-1002.
5. HUGHES, G.R., N.N. HARRIS & A.E. GHARAVI. 1986. The anticardiolipin syndrome. J. Rheumatol. 13: 486-489.
6. KOIKE, T. & E. MATSUURA. 1991. What is the "true" antigen for anticardiolipin antibodies? Lancet 337: 671-672.
7. ASANUMA, Y., A. OESER, A.K. SHINTANI, et al. 2003. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349: 2407-2415.
8. HASUNUMA, Y., E. MATSUURA, Z. MAKITA, et al. 1997. Involvement of β2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin. Exp. Immunol. 107: 569-73.
9. KOBAYASHI, K., E. MATSUURA, Q. LIU, et al. 2001. A specific ligand for β2-glycoprotein I mediates autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages. J. Lipid Res. 42: 697-709.
10. LIU, Q., K. KOBAYASHI, J.-I. FURUKAWA, et al. 2002. Omega-carboxyl variants of 7-ketocholesteryl esters are ligands for β2-glycoprotein I and mediate antibody-dependent uptake of oxidized LDL by macrophages. J. Lipid Res. 43: 1486-1495.
11. KOBAYASHI, K., M. KISHI, T. ATSUMI, et al. 2003. Circulating oxidized LDL forms complexes with β2-glycoprotein I: implication as an atherogenic autoantigen. J. Lipid Res. 44: 716-726.
12. WITZTUM, J. L. & D. STEINBERG. 2001. The oxidative modification hypothesis of atherosclerosis: does it hold for humans? Trends Cardiovasc. Med. 11: 93-102.
13. SCHWENKE, D. C. & T.E. CAREW. 1989. Initiation of atherosclerotic lesions in cholesterol-fed rabbits. II. Selective retention of LDL vs. selective increases in LDL permeability in susceptible sites of arteries. Arteriosclerosis 9: 908-918.
14. KALIORA, A. C., G. V. DEDOUSSIS & H.SCHMIDT. 2006. Dietary antioxidants in preventing atherogenesis. Atherosclerosis 187: 1-17.
15. BERLINER, J. A. & J.W. HEINECKE. 1996. The role of oxidized lipoproteins in atherogenesis. Free Radic. Biol. Med. 20: 707-727.
16. ZHOU, X., G. CALIGIURI, A. HAMSTEN, et al. 2001. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21: 108-114.
17. PALINSKI, W., S. HÖRKKÖ, E. MILLER, et al. 1996. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J. Clin. Invest. 98: 800-814.
18. SHAW, P.X., S. HÖRKKÖ, M.K. CHANG, et al. 2000. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity [In Process Citation]. J. Clin. Invest. 105: 1731-1740.
19. HÖRKKÖ, S., D.A. BIRD, E. MILLER, et al. 1999. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J. Clin. Invest. 103: 117-128.
20. ERKKILÄ, A. T., O. NÄRVÄNEN, S. LEHTO, et al. 2000. Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 20: 204-209.
21. FUKUMOTO, M., T. SHOJI, M. EMOTO, et al. 2000. Antibodies against oxidized LDL and carotid artery intima-media thickness in a healthy population. Arterioscler. Thromb. Vasc. Biol. 20: 703-707.
22. KARVONEN, J., M. PAIVANSALO, Y.A. KESANIEMI, et al. 2003. Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation 108: 2107-2112.
23. WILSON, P. W., O. BEN-YEHUDA, J. MCNAMARA, et al. 2006. Autoantibodies to oxidized LDL and cardiovascular risk: the Framingham Offspring Study. Atherosclerosis 189: 364-368.
24. BOUMA, B., P.G. DE GROOT, J.M. VAN DEN ELSEN, et al. 1999. Adhesion mechanism of human β2-glycoprotein I to phospholipids based on its crystal structure. Embo. J. 18: 5166-5174.
25. SCHWARZENBACHER, R., K. ZETH, K. DIEDERICHS, et al. 1999. Crystal structure of human β2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome. Embo. J. 18: 6228-6239.
26. PRICE, B. E., J. RAUCH, M. A. SHIA, et al. 1996. Anti-phospholipid autoantibodies bind to apoptotic, but not viable, thymocytes in a β2-lycoprotein I-dependent manner. J. Immunol. 157: 2201-2208.
27. NIMPF, J., H WURM, G.M. KOSTNER. 1987. β2-glycoprotein-I (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregation. Atherosclerosis 63: 109-114.
28. LOPEZ, D., K. KOBAYASHI, J.T. MERRILL, et al. 2003. IgG autoantibodies against β2-glycoprotein I complexed with a lipid ligand derived from oxidized low-density lipoprotein are associated with arterial thrombosis in antiphospholipid syndrome. Clin. Dev. Immunol. 10: 203-211.
29. LOPEZ, D., I. GARCIA-VALLADARES, C.A. PALAFOX-SANCHEZ, et al. 2004. Oxidized low-density lipoprotein/β2-glycoprotein I complexes and autoantibodies to oxLig-1/β2-glycoprotein I in patients with systemic lupus erythematosus and antiphospholipid syndrome. Am. J. Clin. Pathol. 121: 426-436.
30. LOPEZ, L.R., B.L. HURLEY, D.F. SIMPSON, et al. 2005. Oxidized low-density lipoprotein/β2-glycoprotein I complexes and autoantibodies in patients with type 2 diabetes mellitus. Ann. N. Y. Acad. Sci. 1051: 97-103.
31. KASAHARA, J., K. KOBAYASHI, Y. MAESHIMA, et al. 2004. Clinical significance of serum oxidized low-density lipoprotein/β2-glycoprotein I complexes in patients with chronic renal diseases. Nephron. Clin. Pract. 98: c15-c24.
32. MOORHEAD, J.F., M.K. CHAN, M. EL-N AHAS, et al. 1982. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 2: 1309-1311.
33. ROH, D.D., V.S. Kamanna & M.A. KIRSCHENBAUM. 1998. Oxidative modification of low-density lipoprotein enhances mesangial cell protein synthesis and gene expression of extracellular matrix proteins. Am. J. Nephrol. 18: 344-350.
34. HASHIMOTO, Y., M. KAWAMURA, K. ICHIKAWA, et al. 1992. Anticardiolipin antibodies in NZW x BXSB F1 mice. A model of antiphospholipid syndrome. J. Immunol. 149: 1063-1068.
35. KUWANA, M., E. MATSUURA, K. KOBAYASHI, et al. 2005. Binding of β2-glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cells. Blood 105: 1552-1557.